logo-loader
Polarean Imaging PLC

Investor Update: Polarean Imaging PLC begins enrolment at third US site

Headlines from the Proactive UK newsroom.

Polarean Imaging (LON:POLX) is on track to complete enrolment for the phase III trial of its MRI drug-device combination this quarter. The first patient has now been enrolled at a third trial site.

Lettings agent Belvoir’s (LON:BLV) first half trading was strong with revenue and operating profit both comfortably ahead of the same period last year. Sales and lettings both grew against a sector backdrop of falling sales activity and the introduction of a ban on tenant fees in June 2019.

Smart meter group CyanConnode (LON:CYAN) has signed a Memorandum of Understanding with China -based Hexing Electrical. Hexing, supplies utilities in more than 80 countries across the world 

HSBC has announced the surprise departure of its group chief executive after just a year and half in the job. John Flint stepped down by mutual consent after the bank said it needed a change in leadership to address a "challenging global environment".

EasyHotel is to be bought by a consortium of Canadian property investors. The price is 95p per share, a premium of 35% to Friday’s close.

Ocado and Marks & Spencer have completed the arrangements for their food delivery joint venture. Consumers will be able to buy M&S products from 1 September with a full range of 6,500 food items available to most of the country.

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.47 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 6 days ago

RNS

Statement on Amphion Innovations

2 weeks, 3 days ago

Total Voting Rights

3 weeks, 5 days ago

Holding(s) in Company

3 weeks, 6 days ago

Holding(s) in Company

3 weeks, 6 days ago

Holding(s) in Company

4 weeks ago

Result of AGM

on 25/7/19

2 min read